JP2008526752A5 - - Google Patents

Download PDF

Info

Publication number
JP2008526752A5
JP2008526752A5 JP2007549552A JP2007549552A JP2008526752A5 JP 2008526752 A5 JP2008526752 A5 JP 2008526752A5 JP 2007549552 A JP2007549552 A JP 2007549552A JP 2007549552 A JP2007549552 A JP 2007549552A JP 2008526752 A5 JP2008526752 A5 JP 2008526752A5
Authority
JP
Japan
Prior art keywords
kit
substituted
amine
irm
ether
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007549552A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008526752A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/047069 external-priority patent/WO2006073940A2/en
Publication of JP2008526752A publication Critical patent/JP2008526752A/ja
Publication of JP2008526752A5 publication Critical patent/JP2008526752A5/ja
Withdrawn legal-status Critical Current

Links

JP2007549552A 2004-12-30 2005-12-28 免疫応答調節剤化合物の多経路投与 Withdrawn JP2008526752A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64087304P 2004-12-30 2004-12-30
PCT/US2005/047069 WO2006073940A2 (en) 2004-12-30 2005-12-28 Multi-route administration of immune response modifier compounds

Publications (2)

Publication Number Publication Date
JP2008526752A JP2008526752A (ja) 2008-07-24
JP2008526752A5 true JP2008526752A5 (enExample) 2009-02-19

Family

ID=36648022

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007549616A Ceased JP2008526757A (ja) 2004-12-30 2005-12-28 免疫応答調節剤製剤および方法
JP2007549552A Withdrawn JP2008526752A (ja) 2004-12-30 2005-12-28 免疫応答調節剤化合物の多経路投与

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007549616A Ceased JP2008526757A (ja) 2004-12-30 2005-12-28 免疫応答調節剤製剤および方法

Country Status (8)

Country Link
US (3) US20080207674A1 (enExample)
EP (2) EP1835915A4 (enExample)
JP (2) JP2008526757A (enExample)
CN (1) CN101443005A (enExample)
AU (2) AU2005323024A1 (enExample)
CA (2) CA2592575A1 (enExample)
WO (2) WO2006073940A2 (enExample)
ZA (1) ZA200706251B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
WO2005018556A2 (en) 2003-08-12 2005-03-03 3M Innovative Properties Company Hydroxylamine substituted imidazo-containing compounds
PH12006500401A1 (en) 2003-08-27 2005-03-10 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
EP1660026A4 (en) 2003-09-05 2008-07-16 3M Innovative Properties Co TREATMENT FOR CD5 + B CELL LYMPHOMA
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
EP1673087B1 (en) 2003-10-03 2015-05-13 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
CA2540598C (en) 2003-10-03 2013-09-24 3M Innovative Properties Company Pyrazolopyridines and analogs thereof
WO2005048945A2 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
EP1685129A4 (en) 2003-11-14 2008-10-22 3M Innovative Properties Co OXIMSUBSTITUTED IMIDAZORING CONNECTIONS
CA2547020C (en) 2003-11-25 2014-03-25 3M Innovative Properties Company 1h-imidazo[4,5-c]pyridine-4-amine derivatives as immune response modifier
US8802853B2 (en) 2003-12-29 2014-08-12 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
WO2005066169A2 (en) 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
AU2005228150A1 (en) 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
ZA200706251B (en) * 2004-12-30 2008-11-26 Coley Pharm Group Inc Immune response modifier formulations and methods
AU2005322898B2 (en) 2004-12-30 2011-11-24 3M Innovative Properties Company Chiral fused (1,2)imidazo(4,5-c) ring compounds
JP5313502B2 (ja) 2004-12-30 2013-10-09 スリーエム イノベイティブ プロパティズ カンパニー 置換キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
CA2597092A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
JP2008530252A (ja) 2005-02-09 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド オキシムおよびヒドロキシルアミンで置換されたチアゾロ［４，５−ｃ］環化合物ならびに方法
WO2006086449A2 (en) 2005-02-09 2006-08-17 Coley Pharmaceutical Group, Inc. Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
AU2006216997A1 (en) 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
CA2597587A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
WO2006091647A2 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
US8178677B2 (en) 2005-02-23 2012-05-15 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinolines
WO2006091568A2 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazonaphthyridines
US8158794B2 (en) 2005-02-23 2012-04-17 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinoline compounds and methods
EP1869043A2 (en) 2005-04-01 2007-12-26 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
EP1863814A1 (en) 2005-04-01 2007-12-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
AU2006287270A1 (en) 2005-09-09 2007-03-15 Coley Pharmaceutical Group, Inc. Amide and carbamate derivatives of N-{2-[4-amino-2- (ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods
ES2429170T3 (es) 2005-11-04 2013-11-13 3M Innovative Properties Company 1H-Imidazoquinolinas sustituidas con hidroxilo y alcoxilo y métodos
US8951528B2 (en) 2006-02-22 2015-02-10 3M Innovative Properties Company Immune response modifier conjugates
US8329721B2 (en) 2006-03-15 2012-12-11 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
WO2008008432A2 (en) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
WO2008030511A2 (en) 2006-09-06 2008-03-13 Coley Pharmaceuticial Group, Inc. Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
WO2010088924A1 (en) * 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
AU2010229835B2 (en) 2009-03-25 2015-01-15 The Board Of Regents Of The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
US20100331812A1 (en) * 2009-06-29 2010-12-30 Nitric Biotherapeutics, Inc. Pharmaceutical Formulations for Iontophoretic Delivery of an Immunomodulator
EP3222621B1 (en) 2010-08-17 2023-03-08 3M Innovative Properties Company Lipidated immune response modifier compound and its medical use
EP3366311B1 (en) 2011-06-03 2020-02-26 3M Innovative Properties Co. Hydrazino-1h-imidazoquinolin-4-amines and conjugates made therefrom
WO2012167088A1 (en) 2011-06-03 2012-12-06 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
WO2015069535A1 (en) * 2013-11-05 2015-05-14 3M Innovative Properties Company Sesame oil based injection formulations
AU2015296214B2 (en) * 2014-08-01 2019-11-07 Board Of Regents, The University Of Texas System Methods and therapeutic combinations for treating tumors
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
WO2017184735A1 (en) * 2016-04-19 2017-10-26 Ifm Therapeutics, Inc Nlrp3 modulators
AU2017252640A1 (en) 2016-04-19 2018-12-06 Innate Tumor Immunity, Inc. NLRP3 modulators
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
CA3086439A1 (en) 2017-12-20 2019-06-27 3M Innovative Properties Company Amide substitued imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA704419B (en) * 1969-07-21 1971-04-28 Ici Australia Ltd Injectable aqueous solutions of tetramisole
DE2423389A1 (de) * 1974-05-14 1975-12-04 Hoechst Ag Arzneimittel mit psychotroper wirkung und verfahren zu ihrer herstellung
US4826830A (en) * 1985-07-31 1989-05-02 Jui Han Topical application of glyciphosphoramide
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
FR2732605B1 (fr) * 1995-04-07 1997-05-16 Pasteur Merieux Serums Vacc Composition destinee a l'induction d'une reponse immunitaire mucosale
JP2002501526A (ja) * 1997-05-29 2002-01-15 アグリサーチ リミティド 乳汁における免疫グロブリンａの生成方法
US6110929A (en) * 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6692745B2 (en) * 2000-01-28 2004-02-17 Arogenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
EP1478371A4 (en) * 2001-10-12 2007-11-07 Univ Iowa Res Found METHOD AND PRODUCTS FOR IMPROVING IMMUNE RESPONSES WITH IMIDAZOCHINOLINE COMPOUNDS
US6677349B1 (en) * 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
WO2004091500A2 (en) * 2003-04-10 2004-10-28 3M Innovative Properties Company Delivery of immune response modifier compounds
MY157827A (en) * 2003-06-27 2016-07-29 3M Innovative Properties Co Sulfonamide substituted imidazoquinolines
AU2004264336B2 (en) * 2003-08-05 2010-12-23 3M Innovative Properties Company Formulations containing an immune response modifier
CU23404A1 (es) * 2003-11-19 2009-08-04 Ct Ingenieria Genetica Biotech Polisacáridos capsulares de neisseria meningitidis como inmunopotenciadores mucosales y formulaciones resultantes
ZA200706251B (en) * 2004-12-30 2008-11-26 Coley Pharm Group Inc Immune response modifier formulations and methods

Similar Documents

Publication Publication Date Title
JP2008526752A5 (enExample)
US9248127B2 (en) Aqueous gel formulations containing immune response modifiers
US8221771B2 (en) Formulations containing an immune response modifier
AU2007345952C1 (en) Positively charged water-soluble prodrugs of 1H-imidazo[4, 5-c]quinolin-4-amines and related compounds with very high skin penetration rates
CA2361936C (en) Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions
ES2541132T3 (es) Método para reducir y tratar la inmunosupresión inducida por UV-B
AU2009210655B2 (en) Treatment of bladder diseases with a TLR7 activator
JP2007521280A5 (enExample)
US20080119508A1 (en) Multi-Route Administration Of Immune Response Modifier Compounds
US20060216333A1 (en) Methods related to the treatment of mucosal associated conditions
RU2005138915A (ru) Сульфонамид замещенные имидазохинолины
RU2003116063A (ru) Сульфонамидоэфирзамещенные имидазохинолины
AU2005244260A1 (en) Methods, compositions, and preparations for delivery of immune response modifiers
JP2007513165A (ja) Ｉｒｍ化合物を含む併用薬および治療方法
CA2468517A1 (en) Thioether substituted imidazoquinolines
JP2005517640A5 (enExample)
ES2291618T3 (es) Composicion farmaceutica a base de un agente inhibidor de la pde4 o de la pde3/4 y de un agente antagonista de receptores de histamina.
AU2003227710A1 (en) New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders
JP2008530014A (ja) １−（２−メチルプロピル）−１Ｈ−イミダゾ［４，５−ｃ］［１，５］ナフチリジン−４−アミンを含む水性ゲル製剤
TW202535906A (zh) 新型短鏈肽及其衍生物
ES2379829T3 (es) Cicatrización de heridas y úlceras mediada por isoniazida
RU2024101306A (ru) Применение соединения для получения лекарственного средства для лечения миелофиброза и сопутствующих симптомов/признаков, и применение указанного соединения
HK1234056B (zh) 1h-咪唑并[4，5-c]喹啉-4-胺类及其相关化合物的前药
NZ613313B2 (en) Pharmaceutical formulation for topical administration comprising b220
NZ613313A (en) Pharmaceutical formulation for topical administration comprising b220